OS Therapies shares are trading higher after the company announced the completion of its Phase 2b clinical trial for OST+HER2 in recurred osteosarcoma and is preparing to request an FDA Type C meeting to adjust protocol. It's data analysis and topline results are expected in Q4 2024.
Portfolio Pulse from Benzinga Newsdesk
OS Therapies shares rise as the company completes its Phase 2b clinical trial for OST+HER2 in recurred osteosarcoma. The company plans to request an FDA Type C meeting to adjust the protocol, with data analysis and topline results expected in Q4 2024.
October 03, 2024 | 7:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OS Therapies' stock is trading higher following the completion of its Phase 2b trial for OST+HER2. The company is preparing for an FDA Type C meeting, with results anticipated in Q4 2024.
The completion of a Phase 2b trial is a significant milestone for OS Therapies, indicating progress in their drug development. The anticipation of an FDA meeting and upcoming results in Q4 2024 adds to investor optimism, likely driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100